284.14
4.89 (1.75%)
| Penutupan Terdahulu | 279.25 |
| Buka | 278.83 |
| Jumlah Dagangan | 25,465 |
| Purata Dagangan (3B) | 297,610 |
| Modal Pasaran | 7,672,458,752 |
| Harga / Pendapatan (P/E TTM) | 10.21 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.41 |
| Harga / Jualan (P/S) | 3.04 |
| Harga / Buku (P/B) | 1.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Keuntungan | -85.16% |
| Margin Operasi (TTM) | 9.72% |
| EPS Cair (TTM) | -76.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -83.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.50% |
| Nisbah Semasa (MRQ) | 5.99 |
| Aliran Tunai Operasi (OCF TTM) | 515.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 250.23 M |
| Pulangan Atas Aset (ROA TTM) | 1.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Bio-Rad Laboratories, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.14% |
| % Dimiliki oleh Institusi | 93.04% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| EDWARDS JEFFREY L | - | - | 0 | 0 |
| HINCKLEY GREG K | - | - | 0 | 0 |
| PEI MELINDA LITHERLAND | - | - | 0 | 0 |
| PINKSTON ARNOLD A | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PINKSTON ARNOLD A | Pengarah | 21 Apr 2026 | Pelaksanaan pilihan | 407 | - | - |
| EDWARDS JEFFREY L | Pengarah | 21 Apr 2026 | Pelaksanaan pilihan | 407 | - | - |
| PEI MELINDA LITHERLAND | Pengarah | 21 Apr 2026 | Pelaksanaan pilihan | 407 | - | - |
| HINCKLEY GREG K | Pengarah | 21 Apr 2026 | Pelaksanaan pilihan | 407 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Jan 2026 | Pengumuman | Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |